Choate, Hall & Stewart

Dr. Brenda Herschbach Jarrell, chair of Choate’s Life Sciences Group, is described by clients as an IP lawyer with keen business savvy. Her extensive technical credentials make her well-versed in a wide variety of technologies in the biotech, pharmaceutical, and specialty chemical industries. She represents companies and institutions at all stages of the life sciences business lifecycle, as well as those who invest in them, guiding IP protection and competitive positioning strategies, negotiating strategic transactions, and providing creative solutions to IP and technology-related challenges. Throughout her career, Brenda has advised multiple clients from Series A through their eventual IPOs.

As one of the foremost respected IP strategists in the country, Brenda is routinely awarded the recognition of “Attorney of the Year” by several respected rankings providers across a variety of categories.

Some of her clients include Adimab, Aleta Biotherapeutics, Angion Biomedica Corp., Apellis Pharmaceuticals, Atlas Venture, Base Genomic, Biogen, BioNTech, Casma Therapeutics, Celsius Therapeutics, Eirion Therapeutics, FogPharma, FORMA Therapeutics, Gilead, Ginkgo BioWorks,  Kernal Biologics, LogicBio Therapeutics, Mereo BioPharma, Olema Pharmaceuticals, Progenics Pharmaceuticals, Regeneron Pharmaceuticals, ReNetX Bio, Scipher Medicine Corporation, STIMIT Corporation, Syros Pharmaceuticals, Third Rock Ventures, WAVE Life Sciences, and Venrock.

Brenda is a member of Choate’s Executive Committee.

Harvard Law School JD, 1998, cum laude University of California at San Francisco PhD, 1993 Biochemistry and Molecular Biology Harvard University MA, 1988, magna cum laude Chemistry Harvard University AB, 1988, magna cum laude Chemistry